CD19-directed CAR-T cell therapy (second/third generation)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD19-directed CAR-T cell therapy (second/third generation), covering 2026-01-05 to 2026-01-05. Get the full timeline:
Most recent: Clinical Trial Update: Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) [Phase 1]